0RQJ logo

Saniona LSE:0RQJ Stock Report

Last Price

SEK 8.45

Market Cap

SEK 1.1b

7D

3.6%

1Y

n/a

Updated

18 May, 2025

Data

Company Financials +

Saniona AB (publ)

LSE:0RQJ Stock Report

Market Cap: SEK 1.1b

0RQJ Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. More details

0RQJ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 89.8% below our estimate of its fair value

Revenue is forecast to grow 11.58% per year

Became profitable this year

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Shareholders have been diluted in the past year


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Saniona AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Saniona
Historical stock prices
Current Share PriceSEK 8.45
52 Week HighSEK 9.83
52 Week LowSEK 1.93
Beta0.80
1 Month Change37.85%
3 Month Change4.45%
1 Year Changen/a
3 Year Change196.49%
5 Year Change-70.34%
Change since IPO-82.43%

Recent News & Updates

Recent updates

Shareholder Returns

0RQJGB BiotechsGB Market
7D3.6%0.1%1.6%
1Yn/a-12.8%0.7%

Return vs Industry: Insufficient data to determine how 0RQJ performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0RQJ performed against the UK Market.

Price Volatility

Is 0RQJ's price volatile compared to industry and market?
0RQJ volatility
0RQJ Average Weekly Movement13.0%
Biotechs Industry Average Movement9.2%
Market Average Movement5.8%
10% most volatile stocks in GB Market11.4%
10% least volatile stocks in GB Market3.2%

Stable Share Price: 0RQJ's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0RQJ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201122Thomas Feldthuswww.saniona.com

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder.

Saniona AB (publ) Fundamentals Summary

How do Saniona's earnings and revenue compare to its market cap?
0RQJ fundamental statistics
Market capSEK 1.15b
Earnings (TTM)SEK 188.71m
Revenue (TTM)SEK 334.67m

6.1x

P/E Ratio

3.4x

P/S Ratio

Is 0RQJ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RQJ income statement (TTM)
RevenueSEK 334.67m
Cost of RevenueSEK 5.10m
Gross ProfitSEK 329.58m
Other ExpensesSEK 140.87m
EarningsSEK 188.71m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 28, 2025

Earnings per share (EPS)1.39
Gross Margin98.48%
Net Profit Margin56.39%
Debt/Equity Ratio2.3%

How did 0RQJ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 01:17
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Saniona AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael NovodNordea Markets
Jesper IlsoeNordea Markets
Fredrik ThorRedeye